Researchers have demonstrated encouraging results in the treatment of Alzheimer’s disease using the experimental drug BAN2401; this treatment significantly slowed clinical cognitive decline and lead to a size reduction in amyloid plaques.
Browsing: drug development
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke.
A preliminary study has revealed that a monoclonal antibody could prevent difficult-to-treat migraines in patients who have tried unsuccessfully to prevent them using other treatments.
Results from the Phase III EXPAND study of siponimod in secondary progressive multiple sclerosis have been announced, revealing that the drug reduced the risk of disability progression.
Ionis Pharmaceuticals recently announced their results from the IONIS-HTT Rx (RG6042) Phase I/II trial, reporting it to be the first drug in development to reduce disease-causing mutant huntingtin protein in people with Huntington’s disease.
The US FDA has issued a refusal-to-file against a key multiple sclerosis drug – ozanimod – due to insufficient data for one of the most important pipeline assets of Celgene.
Howard Fillit, Alzheimer’s Drug Discovery Foundation, introduces non-Alzheimer’s dementias, and explains the current drugs in development for these diseases
Researchers from Queensland University of Technology have identified a drug that could reverse the damaging effects of heavy alcohol consumption on neurogenesis.
Pharmaceutical policy announcements, promising drug trial data and more: check out our round-up of the biggest news from the neuroscience and neurology industry this week
A new study from TauRx reports success in reversing symptoms of Parkinson’s disease in mouse models treated with LTMX.